O-RAN-ALLIANCE
19.1.2023 00:00:40 CET | Business Wire | Press release
New MoU between O-RAN ALLIANCE and ATIS opens the opportunity for ATIS adopting O-RAN specifications
O-RAN ALLIANCE and ATIS signed a Memorandum of Understanding to further both organizations’ mutual objectives to advance the industry towards more intelligent, open, virtualized and global standards-compliant Radio Access Networks (RAN).
“O-RAN is welcoming the opportunity to work with ATIS,” said Alex Jinsung Choi, Chairman of the O-RAN ALLIANCE and SVP Group Technology at Deutsche Telekom. “We look forward to the opportunity to consider ATIS adopting O-RAN specifications for ATIS Open RAN standards and working together to define the next generation of open and intelligent RAN technology.”
O-RAN ALLIANCE event and demos at MWC Barcelona to bring latest updates from the open RAN ecosystem
O-RAN ALLIANCE plans to hold its next industry event on February 28, 2023 from 15:30-16:30 CET at MWC Barcelona 2023, hosted by Deutsche Telekom at Hall 3 Stand 3M31. The event will include:
- Keynotes by Alex Jinsung Choi, Chairman of the O-RAN ALLIANCE and Stefan Engel-Flechsig, O-RAN ALLIANCE’s COO
- Views on open RAN testing & integration and security by CSPs from Asia, Europe and Americas
- Industry panel discussions on regional development (deployments and trials), security, ecosystem maturity and energy efficiency by key CSPs and vendors from the O-RAN ecosystem
Follow our website for speaker lineup and further updates.
More than 60 O-RAN member companies plan to present demonstrations of their O-RAN based technology and solutions at MWC Barcelona or the O-RAN Virtual Exhibition and welcome visitors to join their booths. O-RAN ALLIANCE plans to issue a map of the demos at the exhibition. Follow us on the O-RAN ALLIANCE LinkedIn channel to learn more, closer to the event.
O-RAN Software Community 7th release “G” expanded to 13 project streams
In December 2022, following on the half year release cycle, the O-RAN Software Community (OSC) published its 7th open software release named "G". For the G release, the OSC expanded to 13 project streams, adding a new AI/ML Framework project.
With each release, OSC’s open software continues to greatly help companies to develop, test and integrate their commercial open and intelligent RAN solutions. Contributions to OSC’s open software come from a diverse community, delivering a broad scope of software according to latest O-RAN ALLIANCE specifications.
"I am so delighted to see the 7th release and the addition of the new AI/ML Framework project stream from our open source community," said Chih-Lin I, Chief Scientist from China Mobile and Co-chair of O-RAN Technical Steering Committee. "With O-RAN ALLIANCE moving into its 5th year, we look forward to evolving towards a new phase. I deeply believe that the power of open source is essential in pushing O-RAN's progress to new heights in the coming years."
“The growth of the O-RAN Software Community has been tremendous. With the O-RAN SC G release, this milestone will help further accelerate O-RAN globally and advance the deployment of flexible networks demanding carrier-grade cloud-native infrastructure as we move towards an intelligent systems world fueled by innovative edge applications,” said Gil Hellmann, vice president, Telecom Solutions Engineering, Wind River. “For the latest O-RAN SC G release, Wind River has continued to provide key contributions to the INF project by working with the community to enable more Open RAN related features in StarlingX and implementing a framework supporting the latest published O2 interface, which is pivotal to cloud infrastructure management and deployment operations. We look forward to continuing our close collaboration.”
New Open Testing and Integration Centres (OTIC) approved in Japan and North America
O-RAN ALLIANCE is pleased to announce Japan OTIC and North American OTIC in NYC Metro Area/East (COSMOS) joining the community of Open Testing and Integration Centres. With this addition there are now 9 approved OTICs across Europe, the Americas and Asia.
“Shared testing and integration are key to delivering commercial O-RAN solutions, so it is great to see more OTICs being approved in North America and around the world,” said Igal Elbaz, Network CTO of AT&T and Board member of O-RAN ALLIANCE. “OTICs are also part of O-RAN PlugFests and the O-RAN Certification and Badging program, promoting more confidence in O-RAN products, components, and solutions within the industry.”
"We are delighted with the start of Japan OTIC, pinned by the opening ceremony last month, and believe the neutral and open testing environment for vendors will help to advance O-RAN solutions," said Naoki Tani, EVP and CTO at NTT DOCOMO and Board member of O-RAN ALLIANCE. "NTT DOCOMO has deployed 5G networks nationwide with O-RAN compliant equipment and intends to further expand the O-RAN ecosystem as co-host of Japan OTIC together with YRP R&D Promotion Committee and Japanese operators.”
For more about O-RAN ALLIANCE testing and integration efforts and the OTICs, please visit our website.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 300 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information, please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005984/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom